Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Asif Halimi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0343-8978; OpenAlex author ID A5002744173, A5060489121, A5140656982. Sources: OpenAlex.

Their work

Papers
25 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
139
Papers, trials and grants by year

2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 4 papers · 2026: 8 papers

Papers 25

  1. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  2. Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.12.007↗
  3. Rapid autofluorescence based 3D optical imaging of the pancreatic cancer milieu at mesoscopic scale - stain-free volumetric segmentation. Co-author DOI 10.1038/s41598-026-54433-z↗
  4. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  5. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  6. Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20191-5↗
  7. ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20304-0↗
  8. ASO Author Reflections: Understanding the Prognostic Role of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20312-0↗
  9. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  10. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  11. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  12. Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. Co-author DOI 10.1186/s12893-025-02983-w↗
  13. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Co-author DOI 10.1080/00365521.2024.2378948↗
  14. Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective analysis. Co-author DOI 10.1093/bjsopen/zrae076↗
  15. Surgical resection for pancreatic ductal adenocarcinoma with liver metastasis: is this the beginning of a new era? Co-author DOI 10.21037/hbsn-24-603↗
  16. Portomesenteric venous contact ≤180° and overall survival in resectable head and body pancreatic adenocarcinoma treated with upfront surgery. First author DOI 10.1016/j.ejso.2023.107097↗
  17. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  18. Venous resection for pancreatic cancer, a safe and feasible option? A systematic review and meta-analysis. Co-author DOI 10.1016/j.pan.2022.05.001↗
  19. Metabolic Characterization of Plasma and Cyst Fluid from Cystic Precursors to Pancreatic Cancer Patients Reveal Metabolic Signatures of Bacterial Infection. Co-author DOI 10.1021/acs.jproteome.1c00018↗
  20. Isolation of pancreatic microbiota from cystic precursors of pancreatic cancer with intracellular growth and DNA damaging properties. Co-author DOI 10.1080/19490976.2021.1983101↗
  21. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  22. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  23. In the Era of the Leeds Protocol: A Systematic Review and A Meta-Analysis on the Effect of Resection Margins on Survival Among Pancreatic Ductal Adenocarcinoma… Co-author DOI 10.1177/1457496920911807↗
  24. Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.1016/j.hpb.2018.07.017↗
  25. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. First author DOI 10.1136/gutjnl-2018-317458↗

Closest collaborators

The 25 strongest of 139 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Oskar Franklin · 8 shared papers, 2023–2026 · strength 1.96
  2. Marco Del Chiaro · 9 shared papers, 2019–2026 · strength 1.29
  3. Ernesto Sparrelid · 6 shared papers, 2024–2026 · strength 1.12
  4. Jun Yoshino · 4 shared papers, 2024–2026 · strength 1.01
  5. Nils O. Elander · 4 shared papers, 2025–2026 · strength 0.97
  6. Daniel Öhlund · 4 shared papers, 2025–2026 · strength 0.97
  7. Hanna E. Seppänen · 4 shared papers, 2024–2026 · strength 0.93
  8. Johanna Laukkarinen · 5 shared papers, 2020–2026 · strength 0.88
  9. Thomas F. Stoop · 4 shared papers, 2025–2026 · strength 0.82
  10. Hakon Blomstrand · 3 shared papers, 2026 · strength 0.77
  11. Caj H. Haglund · 3 shared papers, 2026 · strength 0.77
  12. Ella Kesti · 3 shared papers, 2026 · strength 0.77
  13. Malin Sund · 3 shared papers, 2026 · strength 0.77
  14. Benediktas Kurlinkus · 4 shared papers, 2020–2026 · strength 0.72
  15. Eline S. Zwart · 4 shared papers, 2020–2026 · strength 0.72
  16. Reea Ahola · 4 shared papers, 2020–2026 · strength 0.72
  17. Guralp Onur Ceyhan · 4 shared papers, 2020–2026 · strength 0.72
  18. Bas Groot Koerkamp · 5 shared papers, 2020–2026 · strength 0.67
  19. Marc G. Besselink · 5 shared papers, 2020–2026 · strength 0.67
  20. Toshitaka Sugawara · 3 shared papers, 2026 · strength 0.66
  21. Richard David Schulick · 3 shared papers, 2026 · strength 0.66
  22. Roberto Valente · 5 shared papers, 2019–2024 · strength 0.66
  23. Keith John Roberts · 4 shared papers, 2020–2026 · strength 0.64
  24. Geert Kazemier M · 3 shared papers, 2026 · strength 0.60
  25. Poya Ghorbani · 3 shared papers, 2025–2026 · strength 0.58

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.